Claudia Totoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Totoli has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Maria Claudia Cruz Andreoli
Universidade Federal de Sao Paulo, Brasil
3 shared publications - Daniel Ribeiro Rocha
Universidade Federal de São Paulo, Brazil
2 shared publications - Layon Silveira Campagnaro
Universidade Federal de Sao Paulo, Brasil
2 shared publications Adriano Luiz Ammirati
Department of Medicine, Division of Nephrology, Federal University of Sao Paulo, Sao Paulo, Brazil
1 shared publicationAluizio Barbosa Carvalho
Department of Medicine, Division of Nephrology, Federal University of Sao Paulo, Sao Paulo, Brazil
1 shared publication- Maria Eugenia Fernandes Canziani
Universidade Federal de São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 March 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (1) , 1-2
Peritoneal dialysis: why not?
- 1 March 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (1) , 1-2
Open AccessPeritoneal dialysis: why not?
- Open Access
- 1 March 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (1) , 1-2
Diálise peritoneal: por que não?
- 1 March 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (1) , 1-2
Open AccessDiálise peritoneal: por que não?
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (suppl 1) , s37-s44
Peritoneal Dialysis
SUMMARY Peritoneal dialysis (PD) is a renal replacement therapy based on infusing a sterile solution into the peritoneal cavity through a catheter and provides for the removal of solutes and water using the peritoneal membrane as the exchange surface. This solution, which is in close contact with the capillaries in the peritoneum, allows diffusion solute transport and osmotic ultrafiltration water loss since it is hyperosmolar to plasma due to the addition of osmotic agents (most commonly glucose). Infusion and drainage of the solution into the peritoneal cavity can be performed in two ways: manually (continuous ambulatory PD), in which the patient usually goes through four solution changes throughout the day, or machine-assisted PD (automated PD), in which dialysis is performed with the aid of a cycling machine that allows changes to be made overnight while the patient is sleeping. Prescription and follow-up of PD involve characterizing the type of peritoneal transport and assessing the offered dialysis dose (solute clearance) as well as diagnosing and treating possible method-related complications (infectious and non-infectious).
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (suppl 1) , s37-s44
Open AccessPeritoneal Dialysis
SUMMARY Peritoneal dialysis (PD) is a renal replacement therapy based on infusing a sterile solution into the peritoneal cavity through a catheter and provides for the removal of solutes and water using the peritoneal membrane as the exchange surface. This solution, which is in close contact with the capillaries in the peritoneum, allows diffusion solute transport and osmotic ultrafiltration water loss since it is hyperosmolar to plasma due to the addition of osmotic agents (most commonly glucose). Infusion and drainage of the solution into the peritoneal cavity can be performed in two ways: manually (continuous ambulatory PD), in which the patient usually goes through four solution changes throughout the day, or machine-assisted PD (automated PD), in which dialysis is performed with the aid of a cycling machine that allows changes to be made overnight while the patient is sleeping. Prescription and follow-up of PD involve characterizing the type of peritoneal transport and assessing the offered dialysis dose (solute clearance) as well as diagnosing and treating possible method-related complications (infectious and non-infectious).
- Open Access
- 23 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219956
Associated factors related to chronic kidney disease progression in elderly patients
Chronic Kidney Disease (CKD) is a worldwide public health problem. The prevalence of CKD is rising especially in elderly, as consequence of population-ageing related to socioeconomic development and better life expectancy. There are scarce studies evaluating CKD progression and its associated factors in elderly patients. This is a retrospective observational study including 340 patients (≥ 65 years old) CKD stages 3a–5 non-dialysis, incidents in an outpatient CKD clinic, followed by 2.1 years. CKD progression was assessed by the slope of eGFR calculated by CKD-EPI and BIS 1 equations. The patients were divided in progressor and non-progressor groups (eGFR slope < or ≥ 0 mL/min/1.73 m2/year, respectively). Kidney function declined in 193 (57%) patients. In this group, the progression rate was -2.83 (-5.1 / -1.1) mL /min /1.73 m2 /year. Compared to non progressor, the progressor patients were younger [72 (69–78) vs. 76 (69–80) years; p = 0.02]; had higher proportion of diabetic nephropathy, higher serum phosphorus [3.8 (3.3–4.1) vs. 3.5 (3.9–4.1) mg/dL; p = 0.04] and proteinuria [0.10 (0–0.9 vs. 0 (0–0.3)] g/L; p = 0.007)] at the admission. In the logistic regression analysis adjusted for gender and eGFR, proteinuria was independently associated with CKD progression [OR (Odds Ratio) (1.83; 95% CI, 1.17–2.86; p < 0.01)]. CKD progression was observed in the majority of elderly CKD patients and proteinuria was the most important factor associated to the decline of kidney function in this population.
- 23 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219956
Open AccessAssociated factors related to chronic kidney disease progression in elderly patients
Chronic Kidney Disease (CKD) is a worldwide public health problem. The prevalence of CKD is rising especially in elderly, as consequence of population-ageing related to socioeconomic development and better life expectancy. There are scarce studies evaluating CKD progression and its associated factors in elderly patients. This is a retrospective observational study including 340 patients (≥ 65 years old) CKD stages 3a–5 non-dialysis, incidents in an outpatient CKD clinic, followed by 2.1 years. CKD progression was assessed by the slope of eGFR calculated by CKD-EPI and BIS 1 equations. The patients were divided in progressor and non-progressor groups (eGFR slope < or ≥ 0 mL/min/1.73 m2/year, respectively). Kidney function declined in 193 (57%) patients. In this group, the progression rate was -2.83 (-5.1 / -1.1) mL /min /1.73 m2 /year. Compared to non progressor, the progressor patients were younger [72 (69–78) vs. 76 (69–80) years; p = 0.02]; had higher proportion of diabetic nephropathy, higher serum phosphorus [3.8 (3.3–4.1) vs. 3.5 (3.9–4.1) mg/dL; p = 0.04] and proteinuria [0.10 (0–0.9 vs. 0 (0–0.3)] g/L; p = 0.007)] at the admission. In the logistic regression analysis adjusted for gender and eGFR, proteinuria was independently associated with CKD progression [OR (Odds Ratio) (1.83; 95% CI, 1.17–2.86; p < 0.01)]. CKD progression was observed in the majority of elderly CKD patients and proteinuria was the most important factor associated to the decline of kidney function in this population.